Novartis' drug Revolade was associated with increases in platelet counts and reductions in bleeding in a long-term trial involving patients with chronic and persistent immune thrombocytopenia.
Novartis: Revolade promising in trial for immune thrombocytopenia
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.